Clinical trials
Refractory Medulloblastoma clinical trials
Below are recruiting refractory medulloblastoma clinical trials, each written for real people, not researchers. We’re tracking 7 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT07698899RecruitingPhase 1
Study of a new treatment for childhood brain and CNS cancers
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
Basking Ridge, New JerseyAges 3–22 - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT03911388RecruitingPhase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Birmingham, AlabamaAges 3–22
Hear when a new Refractory Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory medulloblastoma?
- Yes. Clin2 currently lists 7 recruiting refractory medulloblastoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory medulloblastoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory medulloblastoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.